Physician profile
Daniel A Bee
NPI 1316914633
$5,476.20
in general payments reported to CMS, 2019-2025
29 companies · $65.58 in 2025
The $65.58 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $556 · 2020: $977 · 2021: $1,016 · 2022: $893 · 2023: $1,007 · 2024: $961 · 2025: $65.58.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,023 · Education: $11.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,022.56 |
| Education | $11.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,119.11 | 2019-2025 | Ozempic, Rybelsus, Saxenda |
| Abbvie INC. | $625.72 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Lilly USA, LLC | $624.67 | 2019-2024 | Mounjaro, Zepbound, Trulicity |
| Pfizer INC. | $586.03 | 2019-2024 | |
| Glaxosmithkline, LLC. | $522.52 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $420.07 | 2019-2024 | Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $238.12 | 2020-2023 | Jardiance |
| Merck Sharp & Dohme LLC | $199.82 | 2019-2024 | M-M-R II, Gardasil 9, Vaqta |
| Amarin Pharma, INC. | $171.41 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $127.92 | 2019-2024 | Eliquis, Camzyos |
| Abbott Laboratories | $78.09 | 2021-2023 | Freestyle Libre 3 |
| Shield Therapeutics INC | $74.99 | 2023-2024 | Accrufer |
| Exact Sciences Corporation | $74.96 | 2023-2024 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $70.98 | 2020-2021 | |
| Amgen INC. | $64.47 | 2020-2024 | Repatha, Otezla |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $57.06 | 2021-2024 | Gvoke Hypopen |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $56.72 | 2023-2024 | Xifaxan, Trulance |
| Dexcom, INC. | $44.10 | 2023-2024 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $42.30 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $42.28 | 2023-2024 | |
| Astellas Pharma US INC | $40.62 | 2022 | |
| Mylan Specialty L.P. | $32.74 | 2024 | Yupelri |
| Sunovion Pharmaceuticals INC. | $31.18 | 2021-2022 | |
| Edwards Lifesciences Corporation | $29.85 | 2022 | |
| Novartis Pharmaceuticals Corporation | $28.70 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $23.39 | 2023 | Rexulti |
| Boston Scientific Corporation | $21.08 | 2022 | |
| Esperion Therapeutics, INC. | $17.30 | 2021 | |
| United Therapeutics Corporation | $10.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Bee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.